Ontology highlight
ABSTRACT:
SUBMITTER: Ionescu DN
PROVIDER: S-EPMC6023555 | biostudies-literature | 2018 Jun
REPOSITORIES: biostudies-literature
Ionescu D N DN Downes M R MR Christofides A A Tsao M S MS
Current oncology (Toronto, Ont.) 20180628 3
Checkpoint inhibitors targeting the programmed cell death 1 protein (PD-1) and programmed cell death ligand 1 (PD-L1) are demonstrating promising efficacy and appear to be well tolerated in a number of tumour types. In non-small-cell lung cancer, head-and-neck squamous cell carcinoma, and urothelial carcinoma, outcomes appear particularly favourable in patients with high PD-L1 expression. However, assays for PD-L1 have been developed for individual agents, and they use different antibody clones, ...[more]